BA.2, a more infectious subvariant to omicron is rapidly spreading around the world and may soon be the predominant version of Covid-19.

The top variant is in at most 18 countries. This strain has been rapidly expanding and now accounts for 35% to all genetically sequenced new cases. That’s up from 10% and 21% the previous week, new World Health Organization data shows. According to the Centers for Disease Control and Prevention, BA.2 is currently responsible for 3.8% of all genetically-sequed Covid cases in the United States.

The public is anxious about a pandemic and wants to find out two things. Will BA.2 lead to a new surge in omicron-related cases? And will more severe infections be contracted by BA.2? Both questions have been answered by scientists so far.

Scientists from Denmark confirmed that this subvariant could infect those who have had omicron before, but it isn’t very common. The subvariant is also more easily spread than BA.1, the original form of Omicron. This version continues to circulate around the world.

It’s not, however, causing a new wave of omicron infection. Globally, Covid cases have plunged 21% over the past week — subsiding in every region except the Western Pacific — while deaths have fallen 8% over the past week, according to data from the WHO.

Maria Van Kerkhove is the technical leader for Covid-19 at WHO. She said that the WHO closely monitors countries who have found BA.2, and so far, there has not been a new surge in cases.

Van Kerkhove stated that, despite the decline in case numbers in some countries, there is no increase in BA.2 during an interactive question and answer session on Tuesday.

This is what we know so far about the subvariant.

Omicron BA.2 has a higher transmissibility than BA.1, according to a group of scientists associated with the University of Copenhagen. wrote in a study last monthThis has not been peer reviewed.

U.K. Health Security Agency found in late JanuaryBA.2 was able to outperform BA.1 in England by a significant margin. The agency’s chief medical adviser, Dr. Susan Hopkins said that they now know that BA.2 is experiencing an increase in growth rates which can be observed in all parts of England.

Mehul Subhar, Emory University’s virologist, stated, “If it is true, that BA.2 may be slightly more transmissible,”

Suthar stated that it doesn’t mean BA.2 would cause a new wave of infection. Suthar stated that BA.2’s potential to create another wave of infection depends on its ability to reinfect those who have recovered from the omicron.

“The reinfection rate is low considering the number of SARS-CoV-2 positive tests. However, it highlights the importance of continuous assessment of how long vaccine-induced immunity and/or natural immunity lasts.” study’s authors wrote.

All of the people infected were able to recover with mild symptoms. A study found that those infected again with BA.2 had lower viral loads, which could indicate some cross-infection immunity.

A separate study was conducted by the U.K. Health Security Agency and found that there were 69 instances of this condition in people. reinfected with BA.2 no more than 90 days after their first infectionCovid. There was no evidence that people were re-infected with BA.2 once they had caught BA.1. This is despite the fact that 51 of them have been identified. Their original Covid cases could be identified by the sequencing and timing of their first infection.

Peer reviewed research is the standard of academic publishing. Because of the panic caused by the pandemics, scientists published their research as soon as they could.

WHO in a statement TuesdayData from the early study of reinfections in the general public shows that one case with BA.1 is strong enough to protect against reinfection by BA.2.

Andrew Pekosz from John Hopkins University said, “It could be that BA.2 sees, from its standpoint, the unfortunate situation of coming into a populace that has a lot preexisting immunity that targets them and that may account for why we aren’t seeing it grow as rapidly as the BA.1 Omicron.”

It is a large and well-respected company. real-world study in South AfricaThe peer-reviewed study that has not yet been published found that BA.2 can cause illness similar to BA.1 Omicron. However, it doesn’t generally make people as sick or as severe as the delta variant. BA.2 is generally not associated with more severe diseases.

South Africa’s National Institute for Communicable Diseases reported that 3.6% were admitted for BA.2 compared to 3.4% for BA.1. The 30% who had BA.2 hospitalizations were more severely ill than the 33% who received BA.1. This study was based upon more than 95,000 patients who had been tested for Covid between December and January.

One of the study’s author, Cheryl Cohen said that BA.2 is very similar in clinical severity to BA.1. However, there was a lower clinical severity than the previous variants, specifically the delta.

WHO officials repeated their belief that the WHO does not recognize any of these issues. no indication BA.2 is more severe.Cohen stated that the South Africa data was reassuring. However, she cautioned against making conclusions about other countries from these results.

Cohen stated, “We need to be cautious when extrapolating other places to, especially other countries where the majority of immunity comes from vaccination in comparison to South Africa, where the vast majority of immunity comes from natural infection.” The natural infection of BA.1/BA.2 could provide stronger protection than being vaccinated.

One study showed that mutations in the BA.2 spike protein could cause more severe lung infections in hamsters, than BA.1. To infect cells, the virus makes use of the spike protein. Vaccines are designed to target this protein and block the infection. The team of Japanese scientists who ran the research The WHO is advised to designate BA.2 as an independent variant of concern.

Emory’s Vizologist Suthar advised caution in interpreting Japanese results because the study doesn’t actually use BA. Mutations on a single virus component, like the spike, do not necessarily indicate whether the virus has more severity.

Although the research has not been peer reviewed, one scientist suggested that they may have to change their findings in order for them to be accepted by the world. They used an engineered BA.2 as a test of their hypothesis. According to Takashi, Takashi Irie was one of the researchers on this study. The team used BA.2’s spike protein and swapped it for the original Wuhan virus. In an email to CNBC Irie acknowledged that more reports show no increased severity of BA.2 than BA.1.

Irie explained that the study that found BA.2 to be more deadly than BA.1 did not necessarily reflect the true results. But, Irie said that his study does show that mutants of the BA.2 surge are capable to causing severe infections.

separate study from JapanThe subvariant of the BA.2 virus was isolated from an Indian traveler. It had similar severity to BA.1 infection in mice and rats. This study was not peer reviewed.

It WHO’s Covid variant advisory groupBefore deciding that BA.2 should be kept classified as an omicron, rather than a distinct variant of concern, the WHO considered both South Africa’s and Japanese studies. According to this, the WHO currently doesn’t consider BA.2 an increased threat to global healthcare than omicron.

Research has shown that the original BA.1 omicron strain was able to escape vaccine-induced antibodies, which led to numerous breakthrough infections in the current surge. Danish scientists have found that BA.2 has a better ability to avoid vaccine protections than BA.1, according a study. study published Last month.

According to the study, breakthrough cases of the virus are less common in vaccinated individuals than those who have not been vaccinated. Scientists believe this is because vaccine-vaccinated people have lower viral loads than those who haven’t received them. The vaccines are still helping to reduce the spread of this virus.

Researchers at Beth Israel Deaconess Medical Center, Boston discovered that BA.2 is able to evade the antibodies of two doses of Pfizer slightly better than BA.1. Similar to BA.2, neutralizing antibody levels were about 1.5 times lower. according to a study published in early February.

Dan Barouch of Harvard’s Center for Virology and Vaccine Research said that BA.2 evades the antibodies from Pfizer vaccines similar to BA.1, although slightly more, but not drastically more. Barouch also helped develop Johnson & Johnson’s Covid vaccine.

Barouch claimed that people who were vaccinated for BA.1 infection also had strong antibodies to BA.2. It would seem that, since BA.1 has been extremely widespread, these people likely have a substantial level of immunity against BA.2, he stated.

A report by the U.K. Health Security Agency published February 24, showed that both vaccines for symptomatic diseases were less effective than those against BA.1. The protection against BA.1 was 69%, while the 74% for BA.2 protection was 74% two weeks later. according to the U.K. study.